Ginah Nightingale1, Emily Hajjar2, Krystal Guo3, Stephanie Komura4, Eric Urnoski5, Jocelyn Sendecki6, Kristine Swartz7, Andrew Chapman8. 1. Department of Pharmacy Practice, Jefferson College of Pharmacy, Philadelphia, PA, USA. Electronic address: ginah.nightingale@jefferson.edu. 2. Department of Pharmacy Practice, Jefferson College of Pharmacy, Philadelphia, PA, USA. 3. Department of Pharmacy Practice, Loma Linda University Medical Center, Loma Linda, CA, USA. 4. Department of Pharmacy, Robert Wood Johnson University Hospital, New Brunswick, NJ, USA. 5. Department of Pharmacy, Hackensack University Medical Center, Hackensack, NJ, USA. 6. Nonclincal Biostatistics, Janssen Research and Development, Spring House, PA, USA. 7. Department of Family and Community Medicine, Division of Geriatrics and Palliative Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA. 8. Department of Medical Oncology, Jefferson Senior Adult Oncology Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Abstract
OBJECTIVES: The prevalence of complementary and alternative medication (CAM) use in senior adult oncology (SAO) patients is widely variable and little is known about whether polypharmacy (PP) and potentially inappropriate medication (PIM) use influences CAM use given the increased number of comorbidities and polypharmacy. One approach to optimize medication management is through utilization of pharmacists as part of a team-based, healthcare model. MATERIALS AND METHODS: Prevalence of CAM and factors influencing CAM use was examined in a secondary analysis of 248 patients who received an initial comprehensive geriatric oncology assessment between January 2011 and June 2013. Data was collected from electronic medical records. CAM was defined as herbal medications, minerals, or other dietary supplements, excluding vitamins. Patient characteristics influencing CAM use (e.g. comorbidities, PP and PIM use) were analyzed. RESULTS: Only 234 patients (evaluated by pharmacists) were included in the final analysis. Mean age was 79.9 years [range 61-98]; 64% women, 74% Caucasian, 87% with a solid tumor, mean comorbidities, 7.69. CAM prevalence was 26.5% (n=62) and median CAM use was 0 (range 0-10). The proportion of CAM use (1, 2, and 3) was 19.2%, 6.4%, and 0.4%, respectively. Associations with CAM use (versus no-CAM) were polypharmacy (P=0.045), vision impairment (P=0.048) and urologic comorbidities (P=0.021). CONCLUSIONS: A pharmacist-led comprehensive medication assessment demonstrated a more precise estimation of CAM prevalence in the ambulatory SAO population. CAM use was associated with polypharmacy, ophthalmic and urologic medical conditions. Integrating pharmacists into team-based (geriatric and oncology) care models is an underutilized yet viable solution to optimize medication use.
OBJECTIVES: The prevalence of complementary and alternative medication (CAM) use in senior adult oncology (SAO) patients is widely variable and little is known about whether polypharmacy (PP) and potentially inappropriate medication (PIM) use influences CAM use given the increased number of comorbidities and polypharmacy. One approach to optimize medication management is through utilization of pharmacists as part of a team-based, healthcare model. MATERIALS AND METHODS: Prevalence of CAM and factors influencing CAM use was examined in a secondary analysis of 248 patients who received an initial comprehensive geriatric oncology assessment between January 2011 and June 2013. Data was collected from electronic medical records. CAM was defined as herbal medications, minerals, or other dietary supplements, excluding vitamins. Patient characteristics influencing CAM use (e.g. comorbidities, PP and PIM use) were analyzed. RESULTS: Only 234 patients (evaluated by pharmacists) were included in the final analysis. Mean age was 79.9 years [range 61-98]; 64% women, 74% Caucasian, 87% with a solid tumor, mean comorbidities, 7.69. CAM prevalence was 26.5% (n=62) and median CAM use was 0 (range 0-10). The proportion of CAM use (1, 2, and 3) was 19.2%, 6.4%, and 0.4%, respectively. Associations with CAM use (versus no-CAM) were polypharmacy (P=0.045), vision impairment (P=0.048) and urologic comorbidities (P=0.021). CONCLUSIONS: A pharmacist-led comprehensive medication assessment demonstrated a more precise estimation of CAM prevalence in the ambulatory SAO population. CAM use was associated with polypharmacy, ophthalmic and urologic medical conditions. Integrating pharmacists into team-based (geriatric and oncology) care models is an underutilized yet viable solution to optimize medication use.
Authors: Thuy Koll; Mackenzi Pergolotti; Holly M Holmes; Huibrie C Pieters; G J van Londen; Zachary A Marcum; Amy R MacKenzie; Christopher B Steer Journal: Curr Oncol Rep Date: 2016-08 Impact factor: 5.075
Authors: M-E Rougé Bugat; M Bourgouin; S Gérard; S Lozano; D Brechemier; P Cestac; C Cool; L Balardy Journal: J Nutr Health Aging Date: 2017 Impact factor: 4.075
Authors: Daniela L Stan; Dietlind L Wahner-Roedler; Kathleen J Yost; Thomas Jamie O'Byrne; Megan E Branda; Aaron L Leppin; Jon C Tilburt Journal: J Altern Complement Med Date: 2018 Sep/Oct Impact factor: 2.579
Authors: Massimiliano Berretta; Chiara Della Pepa; Paolo Tralongo; Alberto Fulvi; Ferdinando Martellotta; Arben Lleshi; Guglielmo Nasti; Rossella Fisichella; Carmela Romano; Chiara De Divitiis; Rosaria Taibi; Francesco Fiorica; Raffaele Di Francia; Anna Di Mari; Lino Del Pup; Anna Crispo; Paolo De Paoli; Adriano Santorelli; Vincenzo Quagliariello; Rosario Vincenzo Iaffaioli; Umberto Tirelli; Gaetano Facchini Journal: Oncotarget Date: 2017-04-11
Authors: Celeste L Y Ewig; Yi Man Cheng; Hoi Shan Li; Jasper Chak Ling Wong; Alex Hong Yu Cho; Freddie Man Hong Poon; Chi Kong Li; Yin Ting Cheung Journal: Front Oncol Date: 2021-04-01 Impact factor: 6.244